Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Last trade$1.01
Day change+$0.0681 (+7.23%)
Day range$0.949 – $1.02
Volume10,985,778
Market cap$607M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$605.58M
Price / earnings
—
Price / book
2.67×
Price / sales
2.78×
EV / sales
3.61×
EV / EBITDA
-51.79×
Profitability
Earnings per share
-$0.07
Return on assets
-9.07%
Return on equity
-21.1%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.1×
Current ratio
6.31×
Quick ratio
4.61×
Cash ratio
0.93×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$91.16M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GERN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$60.19M
$57.48M
$51.84M
$48.02M
$47.23M
$49.04M
$39.6M
$47.54M
Cost of revenue
$0
$9.24M
$1.69M
$0
$0
$1.19M
$1.21M
$0
Gross profit
$60.19M
$48.24M
$50.15M
$48.02M
$47.23M
$47.85M
$38.4M
$47.54M
Selling, general and administrative
$35.7M
$38.86M
$35.43M
$41.67M
$39M
$38.56M
$40.02M
$43.37M
Research and development
$12.71M
$22.03M
$14.96M
$13.55M
$21.07M
$21.74M
$15.08M
$23.43M
Total operating expenses
$54.39M
$60.74M
$49.99M
$73.56M
$61.11M
$60.3M
$55.1M
$67.59M
Operating income
$5.8M
-$12.5M
$158K
-$25.54M
-$13.89M
-$12.45M
-$16.7M
-$20.05M
Interest expense
-$7.21M
-$7.15M
-$7.15M
-$7.3M
-$8.64M
-$8.52M
-$8.2M
-$8.71M
Income before taxes
$1.35M
-$16.68M
-$3.64M
-$28.86M
-$18.43M
-$16.38M
-$19.84M
-$25.35M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$1.35M
-$16.68M
-$3.64M
-$28.86M
-$18.43M
-$16.38M
-$19.84M
-$25.35M
Net income attributable to common shareholders
$1.35M
-$16.68M
-$3.64M
-$28.86M
-$18.43M
-$16.38M
-$19.84M
-$25.35M
EBITDA
$5.87M
-$12.52M
-$102K
-$8.42M
-$13.76M
-$12.33M
-$16.57M
-$19.91M
Basic earnings per share
$0.00
-$0.02
-$0.01
-$0.04
-$0.03
-$0.02
-$0.03
-$0.04
Diluted earnings per share
$0.00
-$0.02
-$0.01
-$0.04
-$0.03
-$0.02
-$0.03
-$0.04
Recent news
Company coverage with links to the original publishers.
Geron reported strong Q3 2026 results with RYTELO net product revenue rising 27% year-over-year to $60.1 million, driven by growing adoption in community oncology clinics. The company discontinued its Phase III myelofibrosis trial to focus on commercial priorities and plans a European launch in Germany by year-end using a capital-efficient model. With operating expenses down 9% and $339 million in cash reserves, management is positioned to pursue hematology acquisitions.
Geron Corporation announced it will release its third quarter 2026 financial results on November 4, 2026, before market open, followed by a conference call at 8:00 a.m. Eastern Time. The hematology-focused biopharmaceutical company is advancing its telomerase inhibitor imetelstat (RYTELO®), which is approved for lower-risk myelodysplastic syndromes in the US and EU, with ongoing Phase 3 trials in myelofibrosis and other blood cancers.
Bristol Myers is relying on its growth portfolio including Reblozyl, Opdivo, and other key drugs to drive top-line growth as legacy drug sales decline. Reblozyl sales reached nearly $1.3 billion in H1 2026, up 23% year-over-year, with potential for further growth from new indications. However, the company faces increasing competition from Geron's Rytelo and Keros Therapeutics' elritercept in the MDS and myelofibrosis treatment space.
Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.
Geron Corporation announced it will release its first quarter 2026 financial results on May 6, 2026, followed by a conference call and webcast at 8:00 a.m. Eastern Time. The commercial-stage biopharmaceutical company continues to advance its telomerase inhibitor RYTELO® (imetelstat), which is approved in the U.S. and EU for treating lower-risk myelodysplastic syndromes, and is conducting a Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.